Accueil › Myélome multiple › Caroline du Nord › Charlotte
Essais cliniques pour Myélome multiple à Charlotte, NC
21 études pour Myélome multiple recherchent des participants dans et autour de Charlotte (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Recrutement en coursPhase 3
- Research Site, Charlotte
- Research Site, Charlotte
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Recrutement en coursPhase 1
- Levine Cancer Institute, Charlotte
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Recrutement en coursPhase 4
- Levine Cancer Institute, Charlotte
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Recrutement en coursPhase 2
- Atrium Health, Charlotte
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Recrutement en coursPhase 3
- Levine Cancer Institute, Charlotte
- Novant Health, Charlotte
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1/2
- Atrium Health Levine Cancer Institute, Charlotte
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Recrutement en coursPhase 2
- Atrium Health's Levine Cancer Institute, Charlotte
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Recrutement en coursPhase 3
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Recrutement en coursPhase 1/2
- Atrium Health Levine Cancer Institute /ID# 271510, Charlotte
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Recrutement en coursPhase 3
- Novant Health Cancer Institute, Charlotte
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Atrium Health, Levine Cancer Institute, Charlotte
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Recrutement en coursPhase 1/2
- Research Site, Charlotte
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Recrutement en coursPhase 3
- Research Site, Charlotte
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Recrutement en coursPhase 1/2
- Atrium Health Levine Cancer Institute /ID# 276193, Charlotte
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Atrium Health Levine Cancer, Charlotte
Pre-malignant States to Hematologic Malignancies in Firefighters
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Levine Cancer Institute, Charlotte
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Recrutement en coursPhase 3
- Levine Cancer Institute, Charlotte
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Recrutement en coursPhase 2
- Levine Cancer Institute, Charlotte
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Recrutement en coursPhase 1/2
- Levine Cancer Institute, Charlotte
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Recrutement en coursPhase 3
- GSK Investigational Site, Charlotte
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Levine Cancer Institute, Charlotte
Essais pour Myélome multiple dans d'autres villes
- New York City, NY60 études
- Boston, MA42 études
- Atlanta, GA42 études
- Houston, TX38 études
- Durham, NC37 études
- Nashville, TN32 études
- Denver, CO27 études
- Rochester, MN24 études
- St. Louis, MO24 études
- Columbus, OH24 études
- Baldwin Park, CA23 études
- Edison, NJ22 études
Autres études à Charlotte
- Cancer (tous types)27 études
- Cancer du sein22 études
- Cancer du poumon non à petites cellules19 études
- Leucémie aiguë myéloïde16 études
- Obésité16 études
- Surpoids15 études
- Cancer colorectal13 études
- Cancer de l'ovaire12 études
- Insuffisance cardiaque11 études
- Cancer métastatique11 études
- Carcinome épidermoïde de la tête et du cou10 études
- BPCO9 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.